Objective: Chronic Myeloid Leukaemia (CML) is a clonal disorder in which cells of the myeloid serie undergo excessive proliferation. The characteristic genetic abnormality of the disease, the Philadelphia (Ph) chromosome, results from a reciprocal translocation between the long arms of chromosomes 9 and 22. The molecular consequence of this translocation is the production of fusion protein bcr-abl. Imatinib is an effective agent in treating CML by targeting the constitutively active tyrosine-kinase domain of bcr-abl. The aim of our study is to determine possible effect of use of imatinib on osteoporosis via comparing dual-energy X-ray absorptiometry (DXA) results of CML group and control group.
Subjects and Methods:This study was performed on 20 patients with CML and 20 people in control group who visited Turgut Ozal Medical Center. Both blood and urine analyses in addition to dual-energy X-ray absorptiometry (DXA) measurements were performed at Turgut Ozal Medical Center, Faculty of Medicine, Inonu University. Mann–Whitney U test were used to compare CML patients and controls. A p < 0.05 was considered statistically significant.
Results: The mean-serum level of phosphate in CML group was found significantly lower than the control group (p < 0.05). The mean-urine calcium level of the patients with hypophosphatemia was found significantly higher (p < 0.05) than the patients with normophosphatemia.
Conclusion: The significant correlation between hypophosphatemia and the use of imatinib which has been determined in our study was harmonious with outcomes of previous studies. However, we did not observe a statistically significant correlation between the use of imatinib and osteoporosis in this study.
Manuscripts that are Published Ahead of Print have been peer reviewed and accepted for publication by the Editorial Board of the West Indian Medical Journal. They may appear in their original format and may not be copy edited or formatted in the style guide of this Journal. While accepted manuscripts are not yet assigned a volume, issue or page numbers, they can be cited using the DOI and date of e-publication. See our Instructions for Authors on how to properly cite manuscripts at this stage. The contents of the manuscript may change before it is published in its final form. Manuscripts in this section will be removed once they have been issued to a volume and issue, but will still retain the DOI and date of e-publication.